Celldex Therapeutics (CLDX) is a biotech company focused on immunology with a market cap of $1.76 billion. Their lead program, barzolvolimab, has shown positive results in clinical trials for various allergic and inflammatory disorders. Celldex is also working on CDX-622 and has a good safety profile with cash reserves to last until 2027.

Viking Therapeutics (VKTX) is valued at $3.58 billion and focuses on metabolic and endocrine disorders. Their lead obesity treatment, VK2735, showed significant weight loss in Phase 2 trials. Viking has a strong cash balance and is advancing its broader metabolic pipeline, targeting massive markets in obesity and metabolic diseases.

Analysts are optimistic about both stocks, with 13 out of 17 analysts rating CLDX as a “Strong Buy” and 16 out of 18 analysts rating VKTX as a “Strong Buy.” While both stocks are down this year, the average target price for CLDX suggests a 104% upside potential, and for VKTX, a 196% upside potential over the next 12 months.

Read more at Yahoo Finance: 2 ‘Strong Buy’ Growth Stocks With Upside of Around 200%